Analyzing R&D Budgets: Dr. Reddy's Laboratories Limited vs Amicus Therapeutics, Inc.

R&D Strategies: Dr. Reddy's vs. Amicus Therapeutics

__timestampAmicus Therapeutics, Inc.Dr. Reddy's Laboratories Limited
Wednesday, January 1, 20144762400012402000000
Thursday, January 1, 20157694300017449000000
Friday, January 1, 201610479300017834000000
Sunday, January 1, 201714931000019551000000
Monday, January 1, 201827090200018265000000
Tuesday, January 1, 201928637800015607000000
Wednesday, January 1, 202030844300015410000000
Friday, January 1, 202127204900016541000000
Saturday, January 1, 202227667700017482000000
Sunday, January 1, 202315238100019381000000
Monday, January 1, 202422873000000
Loading chart...

In pursuit of knowledge

A Tale of Two R&D Giants: Dr. Reddy's vs. Amicus Therapeutics

In the ever-evolving pharmaceutical landscape, research and development (R&D) budgets are a testament to a company's commitment to innovation. Over the past decade, Dr. Reddy's Laboratories Limited and Amicus Therapeutics, Inc. have showcased contrasting R&D strategies. Dr. Reddy's, a stalwart in the industry, consistently allocated substantial resources, with R&D expenses peaking at approximately $19.4 billion in 2023, marking a 56% increase from 2014. In contrast, Amicus Therapeutics, a nimble biotech firm, saw its R&D spending grow by over 500% from 2014 to 2020, reaching a high of $308 million. However, 2023 witnessed a notable dip in Amicus's R&D budget, highlighting potential strategic shifts or market challenges. This analysis underscores the diverse approaches companies take in their quest for medical breakthroughs, reflecting their unique market positions and growth trajectories.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025